biotech
Novartis Buys Rights to Intecell's Japanese Encephalitis Vaccine Candidate
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on June 14, 2006
Novartis Buys Rights to Intecell's Japanese Encephalitis Vaccine Candidate
Novartis is buying rights to Austrian biotech firm Intercell AG's IC51 experimental vaccine against the tropical disease Japanese encephalitis. IC51 will be an addition to Novartis' portfolio of travel vaccines, which include prophylaxis against diseases such as Hepatitis A, cholera and typhoid fever.

Intercell recently announced favorable results for IC51 in Phase III clinical trials and the vaccine is currently under regulatory review in Europe with an orphan drug status.

Further details from Market Watch.

Permalink: Novartis Buys Rights to Intecell's Japanese Encephalitis Vaccine Candidate
Tags: vaccine  encephalitis  biotech  novartis  rights  japanese+encephalitis  vaccine+candidate  novartis+buys 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/24761
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Novartis Buys Rights to Intecell's Japanese Encephalitis Vaccine Candidate:

  • Currently 9.50/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.50 out of 4 vote(s) cast.
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!